The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKERO THERAPEUTICS INC COM 00973Y108 54,601 2,200,778 SH   SOLE   2,200,778 0 0
ALX ONCOLOGY HLDGS INC COM 00166B105 530,392 9,699,925 SH   SOLE   9,699,925 0 0
APELLIS PHARMACEUTICALS INC COM 03753U106 26,005 411,471 SH   SOLE   411,471 0 0
CHECKMATE PHARMACEUTICALS IN COM 162818108 21,893 3,673,374 SH   SOLE   3,673,374 0 0
ELEVATION ONCOLOGY INC COM 28623U101 35,393 2,608,167 SH   SOLE   2,608,167 0 0
HARMONY BIOSCIENCES HLDGS IN COM 413197104 98,936 3,504,624 SH   SOLE   3,504,624 0 0
IMPEL NEUROPHARMA INC COM 45258K109 24,424 2,759,791 SH   SOLE   2,759,791 0 0
METACRINE INC COM 59101E103 11,625 3,059,123 SH   SOLE   3,059,123 0 0
PHARVARIS N V COM N69605108 42,911 2,303,310 SH   SOLE   2,303,310 0 0
VERONA PHARMA PLC SPONSORED ADS 925050106 1,059 161,897 SH   SOLE   161,897 0 0